WIV04 strain vaccine
An inactivated virus vaccine.
General information
A candidate vaccine from inactivated SARS-CoV-2 WIV04 strain with satisfactory clinical phase I and II trial results (Xia et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
Phase II clinical trial Phase I clinical trial Randomized controlled double-blind trial Mixed substance |
Patients | 45.54 | Combined results of two clinical trials (phase I and II) suggest that the inactevated SARS-CoV-2 vaccine is well-tolerated and produces satisfactory immune response. Repeated and longer-interval administration of the vaccine increases antibody responses. Sample size: 72 + 24 control (phase I); 168 + 56 control (phase II). Dosage: 2.5, 5, and 10 μg/dose at days 0, 28, and 56 (phase I); 5 μg/dose at days 0 and 14 or 0 and 21 (phase II). Endpoints: Adverse effects and immunogenicity. |
Aug/13/2020 |
